other-cancer
Neuroblastoma and paraganglioma are both cancers arising from the sympathoadrenal lineage (cells near the adrenal gland), yet they can appear quite different. How they're related developmentally and why they're so heterogeneous has been unclear.
sarcoma
Overloading cancer cells’ protein quality control triggers self-destruction — a new strategy for hard-to-treat tumors. Every living cell carefully balances its protein inventory: too many misfolded or aggregated proteins spell disaster. Heat shock factor 1 (HSF1) acts as a master emergency manager, cleaning up protein damage under stress. Cancers exploit HSF1
other-cancer
AI trained on spatial tumor images can distinguish between immune structures that help versus hurt cancer outcomes Tertiary lymphoid structures (TLS) are organized immune cell aggregates that form within tumors, and they're attracting enormous clinical attention — immunogenic TLS correlate with better outcomes and checkpoint therapy response, while tolerogenic
other-cancer
Six Src inhibitors tested in mouth cancer reveal why monotherapy keeps failing — and how to fix it Oral squamous cell carcinoma (OSCC) is a deadly head and neck cancer with limited systemic treatment options. The kinase Src sits at the intersection of multiple cancer-driving pathways and has long been a
breast-cancer
New lab platform mimics how breast cancer cells choose which organs to invade Researchers have developed an ex vivo invasion assay that uses real mouse organ tissue — lungs, liver, and intestine — stripped of cells but with the extracellular matrix (ECM) intact, then sliced and loaded into microfluidic channels. Cancer cells
other-cancer
Improved statistical method for early cancer drug trials better identifies safe and active doses while protecting patients Early-phase (Phase I) cancer trials are designed primarily to find the maximum tolerated dose of a new drug. But the FDA's Project Optimus initiative has pushed for reform, recognizing that the
other-cancer
New tool lets doctors and researchers query a cancer mutation database using plain English through AI chatbots The Clinical Interpretation of Variants in Cancer (CIViC) database is a community-curated resource that links specific genetic mutations to their clinical significance in cancer — what they mean for treatment, prognosis, and drug response.